PhaseBio Pharmaceuticals, Inc. (PHAS)
R&D to Revenue
10066.83%
Quarterly · Period ending:
PHAS R&D to Revenue
Latest reported10066.83%period ending
Latest reported10066.83%period ending
PHAS Quarterly R&D/Revenue (0.00% → 10066.83%)
Latest values, visible window
High-resolution chart · PNG
PHAS r&d to revenue history
Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | R&D to Revenue |
|---|---|
| 10,066.8269% | |
| 12,252.9915% | |
| -47,246.7677% | |
| 7,482.3881% | |
| 264.7127% | |
| 0% | |
| 6,989,687,500,000,000% | |
| 7,226.556% | |
| 2,966.7141% | |
| 3,577.8125% | |
| 1,096.9895% | |
| 3,746.0581% | |
| 1,106.8279% | |
| 876.1103% | |
| 2,208.5603% | |
| 1,059.3674% | |
| 0% | |
| 0% | |
| 0% | |
| 0% |